Navigation Links
'Glow-in-the-dark' red blood cells made from human stem cells
Date:8/24/2009

Victorian stem cell scientists from Monash University have modified a human embryonic stem cell (hESC) line to glow red when the stem cells become red blood cells.

The modified hESC line, ErythRED, represents a major step forward to the eventual aim of generating mature, fully functional red blood cells from human embryonic stem cells.

The research, conducted by a team led by Professors Andrew Elefanty and Ed Stanley at the Monash Immunology and Stem Cell Laboratories that included scientists at the Murdoch Children's Research Institute, was published in today's issue of the prestigious journal, Nature Methods.

The work, funded by the Australian Stem Cell Centre (ASCC), will help scientists to track the differentiation of embryonic stem cells into red blood cells.

Whilst hESCs have the potential to turn into any cell type in the body, it remains a scientific challenge to reliably turn these stem cells into specific cell types such as red blood cells. The development of the ErythRED embryonic stem cell line, which fluoresces red when haemoglobin genes are switched on, is an important development that will help researchers to optimise the conditions that generate these cells.

Professor Joe Sambrook, Scientific Director of the ASCC said that "The elegant work of the Elefanty-Stanley group unlocks the entrance to the long sought and elusive differentiation pathway that leads to expression of adult haemoglobin genes"

"Not only will the ErythRED cell line lead to more efficient creation of red blood cells from human embryonic stem cells, but these cells are a crucial tool for monitoring the behaviour of the cells when transplanted into animal models" said Professor Andrew Elefanty.


'/>"/>

Contact: Samantha Blair
Samantha.Blair@adm.monash.edu.au
61-399-034-841
Monash University
Source:Eurekalert

Page: 1

Related biology news :

1. High blood pressure, low energy -- a recipe for heart failure
2. Right breakfast bread keeps blood sugar in check all day
3. U of M begins nations first clinical trial using T-reg cells from cord blood in leukemia treatment
4. Folic acid lowers blood arsenic levels, according to Mailman School of Public Health study
5. Folic acid lowers blood arsenic levels in Bangladesh
6. Study reveals a key to blood vessel growth and possible drug target
7. Expecting an afternoon nap can reduce blood pressure
8. MIT: blood may help us think
9. Immune cells promote blood vessel formation in mouse endometriosis
10. Elevated nitric oxide in blood is key to high altitude function for Tibetans
11. Fine-tuning lasers to destroy blood-borne diseases like AIDS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/11/2017)... 11, 2017 NXT-ID, Inc. (NASDAQ:   ... announces the appointment of independent Directors Mr. Robin D. ... Board of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , ... forward to their guidance and benefiting from their considerable expertise ...
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
(Date:3/30/2017)... The research team of The Hong Kong ... identification by adopting ground breaking 3D fingerprint minutiae recovery and matching ... and accuracy for use in identification, crime investigation, immigration control, security ... ... A research team led by ...
Breaking Biology News(10 mins):
(Date:4/20/2017)... April 20, 2017 For today, Stock-Callers.com ... novel drug development and clinical research aimed at treating diseases ... (NASDAQ: BSTG), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Kite Pharma Inc. ... ). You can access our complimentary research reports on these ... ...
(Date:4/19/2017)... ... April 19, 2017 , ... Nobilis Therapeutics Announces Completion of Landmark ... Clinical Data in its Upcoming Post Traumatic Stress Disorder Trial , Nobilis Therapeutics, ... trial assessing efficacy of its NBTX-001, a xenon-based therapeutic in the treatment of Panic ...
(Date:4/19/2017)... 2017  As a Bronze Sponsor of ... ,  Proove┬« Biosciences, Inc. announces the first-ever ... lifestyle factors to accurately predict prescription opioid abuse. In ... California (USC), the Interventional Pain Institute in ... showing that Proove Opioid Risk┬« accurately identifies patients ...
(Date:4/18/2017)... (PRWEB) , ... April 18, 2017 , ... ... company, has been awarded Channel Partners 2017 Next-Gen Solution Provider. , Channel Partners ... value for customers with their vision, innovation, and advocacy of the channel during ...
Breaking Biology Technology: